Back to Search
Start Over
Glycogen phosphorylase inhibition improves beta cell function
- Source :
- British Journal of Pharmacology. 175:301-319
- Publication Year :
- 2017
- Publisher :
- Wiley, 2017.
-
Abstract
- Background and Purpose Glycogen phosphorylase (GP) is the key enzyme for glycogen degradation. GP inhibitors (GPi-s) are glucose lowering agents that cause the accumulation of glucose in the liver as glycogen. Glycogen metabolism has implications in beta cell function. Glycogen degradation can maintain cellular glucose levels, which feeds into catabolism to maintain insulin secretion, and elevated glycogen degradation levels contribute to glucotoxicity. The purpose of this study was to assess whether influencing glycogen metabolism in beta cells by GPi-s affects the function of these cells. Experimental Approach The effects of structurally different GPi-s were investigated on MIN6 insulinoma cells and in a mouse model of diabetes. Key Results GPi treatment increased glycogen content and, consequently, the surface area of glycogen in MIN6 cells. Furthermore, GPi treatment induced insulin receptor β (InsRβ), Akt and p70S6K phosphorylation, as well as pancreatic and duodenal homeobox 1(PDX1) and insulin expression. In line with these findings, GPi-s enhanced non-stimulated and glucose-stimulated insulin secretion in MIN6 cells. The InsRβ was shown to co-localize with glycogen particles as confirmed by in silico screening, where components of InsR signalling were identified as glycogen-bound proteins. GPi-s also activated the pathway of insulin secretion, indicated by enhanced glycolysis, mitochondrial oxidation and calcium signalling. Finally, GPi-s increased the size of islets of Langerhans and improved glucose-induced insulin release in mice. Conclusion and Implications These data suggest that GPi-s also target beta cells and can be repurposed as agents to preserve beta cell function or even ameliorate beta cell dysfunction in different forms of diabetes. Linked Articles This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc
- Subjects :
- 0301 basic medicine
Pharmacology
medicine.medical_specialty
biology
Glycogen
Glycogen debranching enzyme
03 medical and health sciences
Glycogen phosphorylase
Insulin receptor
chemistry.chemical_compound
030104 developmental biology
0302 clinical medicine
Endocrinology
chemistry
Glycogenesis
030220 oncology & carcinogenesis
Internal medicine
medicine
biology.protein
Glycogen branching enzyme
Phosphorylase kinase
Glycogen synthase
Subjects
Details
- ISSN :
- 00071188
- Volume :
- 175
- Database :
- OpenAIRE
- Journal :
- British Journal of Pharmacology
- Accession number :
- edsair.doi...........8c4ee3f496f75bc116e876b2e8cc4bc2
- Full Text :
- https://doi.org/10.1111/bph.13819